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Introduction
Intracellular free drug concentration plays a critical role in developing target exposure and pharmacological activity relationships for disease targets located in the intracellular domain. For compounds that reach distribution equilibrium across the cell membrane at steady state, free drug concentration in the media might be considered the same as the intracellular free drug concentration. This is usually the case for most compounds, in which the nominal concentrations can be used to correlate to pharmacological activities (e.g., IC 50 ) of a compound in in vitro assays or after correction of non-specific binding to the proteins/lipids in the assay media. However, when transporters are involved in the distribution process, the intracellular free drug concentration may be different than that in the media due to active processes. In addition, effects of membrane potential, lysosomal trapping, pH gradient and mitochondria accumulation can all impact the intracellular free drug concentration relative to the medium free concentration (Figure 1 ). Therefore, it is important to understand the intracellular free drug concentration and unbound distribution coefficient (K puu ) to accurately determine the true potency of a compound, e.g., intrinsic IC 50 , rather than apparent IC 50 . Prediction of human in vivo liver-to-plasma K puu is of great importance in order to estimate dose, safety margin and drug-drug interaction potentials for compounds with transporter-mediated uptake into the liver. Development of in vitro tools to predict in vivo liver-to-plasma K puu will be very useful for human translation in drug discovery and development, since there are no simple tools available to measure human liver concentration.
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Several in vitro methods have been developed to measure the intracellular free drug concentration and K puu in hepatocytes or transfected cell systems expressed OATP transporters ( Figure 2 ). The binding method measures f ucell , medium and total cell concentration at the steady state, from which intracellular free drug concentration and K puu are determined (Mateus et al., 2013) . The temperature method measures the medium and total cell concentration at both 37°C and 4°C at steady state (Shitara et al., 2013) . The total concentration ratio of cell to medium between 37°C and 4°C is considered to be K puu . This method does not consider the impact of membrane potential or metabolism. The kinetic method measures the uptake rate at multiple concentrations in the presence of CYP inhibitor, ABT. Kinetic parameters (V max , K m , and P diff ) are obtained by simultaneously fitting all the data (Yabe et al., 2011) . K puu is calculated based on the kinetic parameters with the extended sequential clearance equation (Yabe et al., 2011) . This approach does not consider the impact of efflux transport or metabolism on K puu . The permeability method measures the permeability of both neutral and ionized species and determines the K puu across a cell membrane based on membrane potential and passive permeability . This method has not incorporated the effects of transporters or metabolism at this point. Other methods reported to determine drug concentration in the subcellular compartments (Pfeifer et al., 2013) are relevant to therapeutic targets localized in the specific subcellular organelles. Validation of the different K puu methods with in vitro or in vivo data is minimal in literature. We will discuss our approach for measuring K puu and intracellular free drug concentration, as well as validation against in vitro potency, using cell lines expressing different members of the SLC13A family, hepatocytes and in vivo rat liver-to-plasma K puu data. This article has not been copyedited and formatted. The final version may differ from this version. Citrate is a key regulatory metabolic intermediate and is critical in the integration of the glycolysis and lipid synthesis pathways. Inhibition of hepatic extracellular citrate uptake through SLC13A5 has been suggested as a potential therapeutic approach to treat metabolic diseases (Huard et al., 2015; Huard et al., 2016; Li et al., 2016) . The SLC13A family contains five family members: SLC13A1 and SLC13A4 mainly transport sulfate, and SLC13A2, SLC13A3 and SLC13A5 transport di-and tri-carboxylates such as citrate (Lee et al., 2005; Bergeron et al., 2013) . SLC13A5 is highly expressed in human liver, while SLC13A2 and SLC13A3 are expressed more broadly, including in the intestine and kidney (Pajor, 2014) . Therefore, selective SLC13A5 inhibitors have the potential to impact citrate flux in the liver only, while SLC13A2/3 inhibitors can impact citrate flux in the intestine and kidney as well. Development of specific inhibitors for SLC13A5 is proposed to be beneficial in treating metabolic disorders by reducing citrate flux into the liver, and presumably exert the metabolic benefits through modification of intracellular metabolites, while limiting direct effects in other tissues. This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Materials
Test compounds were obtained from Pfizer Global Material Management (Groton, CT) or purchased from Sigma-Aldrich (St. Louis, MO). The syntheses of diacids PF-06649298, PF-06649297 and monoacid PF-06757303 were previously reported (Huard et al., 2015) .
The syntheses of PF-06794266, PF-06793742 and PF-06761281 were also reported (Huard et al., 2016) . PF-06761281 was commercially available via Sigma Aldrich (catalog # PZ0318). The syntheses of PF-06746350 and PF-06741415 were similar to the methods described previously (Huard et al., 2016) . Other reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless specified. The 96-well equilibrium dialysis (HTD96) device and cellulose membranes with MWCO of 12-14K were purchased from HTDialysis, LLC (Gales Ferry, CT). 1.2 mL deep 96-well plates were from Axygen Scientific Inc. (Union City, CA) and pipette tips were obtained from Apricot Designs (Monrovia, CA).
Measurement of Fraction Unbound
Cells (hepatocytes, HEK293 transfected with human SLC13A transporters) at a cell density of 50-60 million cells/mL, rat and human liver tissues (1:5 dilution with phosphate buffered saline (PBS)) were homogenized at room temperature in PBS using an Omni TH tissue homogenizer (Omni International, Kennesaw, GA) with a 7 mm x 110 mm tip at high speed for 30 second pulses. Assay media containing proteins (e.g., BSA) were used directly for binding measurement. The dialysis membranes were prepared prior to experimental setup. The cellulose membranes (MWCO 12-14K) were immersed in de-This article has not been copyedited and formatted. The final version may differ from this version. down, reconstituted and subsequently analyzed using LC-MS/MS. Sertraline was used as a quality control sample on every plate. Cell diameter was measured using ViCELL XR (Beckman-Coulter, Inc., Danvers, MA) to calculate cell volume assuming spherical shape and dilution factor.
In Vitro K puu Measurement
Transfected Cells (SLC13A5-and SLC13A3-HEK293) K puu within this paper is defined as the ratio between unbound intracellular free drug concentration and unbound medium concentration (steady state is not assumed).
Protocols to generate the stable cell line overexpressing sodium citrate transporters and culture conditions were discussed previously (Huard et al., 2015) . Test compounds (1 μM unless otherwise specified) were incubated with the plated cells (1-4 hours unless otherwise specified) at 37 °C in a humidified (75% RH) incubator with 5% CO 2 /95% O 2 .
At the end of the incubation, 100 μL of the media were removed for concentration determination, and cold acetonitrile was added. The rest of the media was gently removed from the cells by pipette aspiration. The cells were washed three times with cold PBS of the same starting volume. After wash, the cells were lysed by adding 80 μL of MPER buffer (Thermo Scientific, Rockford, IL). An aliquot of the lysed cells was transferred to a new plate, matrix matched, and cold acetonitrile containing IS was added.
The solutions were centrifuged at 3000 RPM for 10 min at room temperature. The supernatants were transferred and analyzed by LC-MS/MS against standard curves that were matrix matched for both media and cells.
Human and Rat Hepatocytes
This article has not been copyedited and formatted. The final version may differ from this version. Cryopreserved human hepatocytes (Lot DCM) consisting of 10 donors, both males and females, were custom-pooled and prepared by BioreclamationIVT (Baltimore, MD).
Wistar-Han rat hepatocytes (Lot VSU) consisting 35 male donors were also purchased from BioreclamationIVT. Upon thawing, the hepatocytes were re-suspended in Williams E medium (WEM GIBCO-BRL, custom formula supplemented with 50 mM Hepes and 26 mM sodium bicarbonate). The cells were counted and viability was determined using the Trypan Blue exclusion method. Test compounds were dissolved in DMSO at 1 mM and 1 µL was added to 0.5 million cells/mL suspended hepatocytes in 1000 µL (final concentration 1 µM containing 0.1% DMSO). The suspension was incubated in a humidified (75% RH) incubator at 37 °C with 5% CO 2 /95% O 2 . For rat hepatocytes, InVitroGRO HI media (Fisher Scientific,Waltham, MA) containing 0.2, 2 and 4% fatty acid free BSA (catalog # A4612, Sigma-Aldrich, St. Louis, MO) were also used in the study for IVIVE development. At appropriate time points, hepatocyte suspension was centrifuged at 500 RPM for 3 minutes and supernatant was collected and removed from the cells to determine the medium concentration. Cells were washed 3 times with cold PBS (1 mL each) and lysed by adding 80 μL of MPER buffer (Thermo Scientific, Rockford, IL). An aliquot of the lysed cells, as well as the medium supernatant, were transferred to a new plate, matrix matched, and cold acetonitrile containing IS was added.
Stability in Human Hepatocytes and Media
This article has not been copyedited and formatted. The final version may differ from this version. The experimental details and data processing have been reported previously (Di et al., 2012) . 1 µM test compound was added to cryopreserved human or rat hepatocytes at 0.5 million cells/mL in assay media and incubated in a humidified (75% RH) incubator at 37 °C with 5% CO 2 /95% O 2. At appropriate time points, an aliquot of the suspension was collected and quenched with cold acetonitrile containing IS. The solutions were centrifuged at 3000 RPM for 10 min at room temperature. The supernatants were transferred and analyzed by LC-MS/MS.
In Vivo Rat Liver-to-Plasma K puu Determination
The rat intravenous (I.V.) infusion study was conducted at BioDuro contract laboratories (Shanghai, China). Rats (Wistar-Han, male, fed, n=3) were I.V. infused via a jugular vein cannula (JVC) with test compounds for 6 hours at an infusion rate of 5 -9 μL/min using a Harvard 2000 programmable pump (Harvard Apparatus, Holliston, MA). The doses were 1.6 (PF-06649298), 0.21 (PF-06761281) and 5.5 (PF-06741415) mg/kg, which were estimated based on I.V. bolus dose and modeled using a two compartment model (Phoenix WinNonlin 6.3, Princeton, NJ). Compounds were formulated in 2% PEG400 (polyethylene glycol 400) and 98% of a 15% SBECD (sulfobutylether-βcyclodextrin) in water. Blood samples were collected from the carotid artery catheter at 0, 1, 2, 4 and 6 hours to determine time required to achieve steady state. Upon study termination, livers were collected and concentrations were determined. Free concentrations were determined by multiplying the steady state total plasma and liver concentration by fraction unbound of plasma or liver. In vivo free liver-to-plasma ratio, This article has not been copyedited and formatted. The final version may differ from this version. 
LC-MS/MS Quantification
A typical LC-MS/MS method is described here and equivalent methods were also used depending on sample characteristics. The LC mobile phases were either: (A) HPLC grade water containing 0.1% formic acid, (B) acetonitrile containing 0.1% formic acid, or (A) 95% 2 mM ammonium acetate in water and 5% 50/50 methanol/acetonitrile, (B) 90% 50/50 methanol/acetonitrile and 10% 2 mM ammonium acetate in water. A solvent gradient from 5% (B) to 95% (B) over 1.1 minutes at the flow rate of 0.5 mL/min was used to elute the compounds from the column (Waters UPLC BEH C18, 50x2.1 mm, 1.7 μ m, Waters, Milford, MA). The total run-time was 2.5 minutes / injection. An aliquot of 10 μ L sample was injected for analysis using a CTC PAL autosampler (LEAP Technologies, Carrboro, NC). The analysis was conducted with Agilent 1290 binary pump (Santa Clara, CA) connected to an AB Sciex (Foster City, CA) API 6500 triple quadrupole mass spectrometer equipped with a TurboIonSpray source using MRM mode.
Analyst™ 1.6.1 software (Applied Biosystems, Foster City, CA) was applied to data collection processing and analysis.
Calculation Methods
Fraction unbound was calculated using Equation (1 (2) and (3) were used for calculation, where D is the dilution factor (Kalvass and Maurer, 2002) . Dilution factor for cells is calculated based on medium to cell volume (calculated from cell diameter assuming a sphere geometry) and cell density. Recovery and stability were calculated using Equation (4) and Equation (5), respectively. In vitro K puu , unbound cell concentration and unbound medium concentration were calculated by Equations (6) - (8).
C u,cell = C total,cell x f u,cell Eq (7) C u,medium = C total,medium x f u,medium Eq (8)
Modeling Method for in Vitro K puu for Ethyl Ester Prodrug and Active Diacid
Prodrug PF-06757303 enters into hepatocytes by transcellular passive diffusion where it can be converted to active diacid PF-06649298 in hepatocytes by esterases ( Figure 3 ).
( Figure 4A ), two active processes were modeled, i.e, the influx of the compound from medium to hepatocyte and the efflux of the compound from hepatocyte to medium. Since PF-06649298 was stable in human hepatocytes, no metabolism was considered. The PF-06649298 medium and hepatocyte concentrations time course were modeled using differential equations (9) and (10), where A is amount (nmoL); P is influx or efflux rate constant (mm/min); SA is surface area of hepatocytes (mm 2 ); fu is fraction unbound; V is volume (µL); '8' represents PF-06649298; 'in' represents the flux into hepatocytes; 'out' represents the flux out of hepatocytes; 'm' represents media, and 'c' represents hepatocytes. The resulting K puu of PF-06649298 was the ratio of the influx and efflux rate constant. Model parameters are summarized in the supplementary material (Table 1S) .
Eq (10) For human hepatocyte suspension incubation with ester PF-06757303 ( Figure 4B ), in addition to the influx and efflux processes, the conversion of ester PF-06757303 to diacid PF-06649298 in the hepatocytes was included. PF-06757303 was found to be highly permeable and no active cellular uptake was observed. Therefore, prodrug PF-06757303
can enter into hepatocytes only by passive diffusion. Time course of medium and hepatocyte concentrations of diacid PF-06649298 and prodrug PF-06757303 was simulated using differential equations (11 -14), where '3' represents PF-06757303, and (9) and (10).
Eq (14) This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Enantioselectivity of K puu for Sodium Citrate Transporter
The K puu values of a set of sodium citrate transporter inhibitors in human hepatocytes, which express high level of SLC13A5, are shown in Table 1 . K puu within this paper is defined as the ratio between unbound intracellular free drug concentration and unbound medium concentration (steady state is not assumed). The pharmacologically active Renantiomers all achieved moderate to high K puu values (from 4.8 to 61) in human hepatocytes, while the pharmacologically inactive S-enantiomers all had low K puu (< 1).
The data demonstrated that SLC13A5 was highly enantioselective towards the Renantiomer by active influx of its substrates into the hepatocytes. The diacidic sodium citrate transporter inhibitors from this series had minimal metabolic turnover in the human hepatocytes and very low transcellular passive permeability (Huard et al., 2016) leading to high K puu through active uptake processes. Enantioselective transport uptake and inhibition had been reported in literature (Honjo et al., 2011; Togami et al., 2013) , however, the differences in uptake are particularly striking for the two enantiomers in this case.
Correlation of K puu to In Vitro Pharmacological Activity
Human hepatocytes and HEK293 cells expressing SLC13A transporters were used to determine the K puu and in vitro IC 50 values for inhibition of SLC13A transporters (Huard et al., 2015; Huard et al., 2016) for a pair of enantiomers PF-06649298 (R) and PF-06649297 (S) ( of the diacids in the absence of transporter-mediated uptake in cells (e.g., in HEK293 cells). The K puu values are consistent with the in vitro pharmacological activity of SLC13A5 inhibition (Table 2) . When comparing IC 50 values based on nominal concentration for PF-06649298, the human hepatocyte IC 50 is 39-fold higher than that in the SLC13A5 HEK293 cells (Table 3) . However, after correction for intracellular free drug concentration using K puu at each test concentration (data not shown, K puu values varied with concentrations), the IC 50 in the two cell-based systems are comparable (Table   3 ), suggesting SLC13A5 is inhibited at least in part from the intracellular domain. This exemplifies the importance of measuring intracellular free drug concentration to build a correlation with pharmacological activity for intracellular targets. The high K puu value of PF-06761281 in SLC13A3 transfected HEK293 cells (Table 2) supports that active uptake of this compound by SLC13A3 in intestine may play a role in oral absorption and at least partially explains the difference in fraction absorbed (f a ) compared to PF-06649298 (Huard et al. 2016 ). Both PF-06649298 (R) and PF-06649297 (S) have a rat f a ~ 0.2, presumably through passive paracellular diffusion (Huard et al., 2016) . Conversely, PF-06761281 (R), a substrate for SLC13A3, has a rat f a of 1 while its enantiomer PF-06761282 (S) has a rat f a of 0.07, suggesting that transport of the diacids by SLC13A3 is also enantioselective (Huard et al., 2016) .
Comparison between in Vitro and in Vivo K puu (IVIVE)
In vivo liver-to-plasma unbound concentration ratios at the steady state (in vivo K puu )
were determined using rat I.V. infusion. The comparison of in vitro K puu in rat hepatocyte suspensions with various amounts of BSA and in vivo liver-to-plasma K puu is shown in Table 4 . The differences of sodium concentrations in the system that have various amounts of BSA are small and the impact on the SCL13A5 uptake is expected to be minimal. In general, the in vitro hepatocyte K puu with 4% BSA is in good agreement with in vivo liver-to-plasma K puu. PF-06649298 shows high K puu in vitro and in vivo (14 vs. 16), while PF-06761281 and PF-06741415 have low/moderate in vitro and in vivo K puu . The differences are within assay variability from both in vitro (liver and plasma binding, K puu from multiple rat hepatocyte donors) and in vivo (individual differences).
The data suggest that the in vitro suspension hepatocyte system could potentially be used to predict in vivo K puu, which is important to estimate liver concentrations in humans (difficult to measure directly), develop PK/PD relationships and predict drug-drug interaction potentials. In vitro K puu is sensitive to the amount of BSA in the assay media with 4% (plasma physiological amount) giving the best correlation to in vivo data.
K puu Measurement for Prodrug and Active Diacid
This article has not been copyedited and formatted. The final version may differ from this version. Prodrug is a strategy that can be used to enhance oral bioavailability and the ethyl ester prodrug (PF-06757303) of diacid PF-06649298 was prepared (Figure 3) . The conversion rate from prodrug PF-06757303 to the active diacid PF-06649298 and the K puu in human hepatocytes are summarized in Figures 5-6 and Table 5 [model parameters (Table 1S) and diagnosis plots of model fitting ( Figure 1S ) are in the supplementary material).
When human hepatocytes in suspension were incubated with diacid PF-06649298, the medium concentration remained relatively unchanged at 1 µM over 2 hours (Figure 5A , due to the large volume difference between cells and media), while the intracellular free drug concentration increased gradually to a K puu of 3 at 2 hours ( Figure 5B , Table 5 ).
When human hepatocytes in suspension were incubated with ethyl ester PF-06757303, the medium and cell concentration of the ester decreased due to conversion to the corresponding diacid ( Figures 6C and 6D) , while the concentration of the diacid increased in both the media and hepatocytes (Figures 6A and 6B) . The respective K puu of ester PF-06757303 and diacid PF-06649298 were 0.07 and 59 at 2 hours ( Table 5 ). The K puu value measured for diacid PF-06649298 was higher when the cells were treated with the prodrug rather than the diacid directly (59 vs. 3). The combination of high formation rate (rapid entry of the prodrug into the hepatocytes and fast conversion to the diacid by esterases within the cells) and the slow disappearance rate (low passive diffusion, no active efflux out and minimal metabolism) lead to a high K puu value for the diacid. For the prodrug, its disappearance rate (passive diffusion out of the cells and rapid conversion to the diacid) is much faster than its appearance rate (passive diffusion into the cells), leading to a less than one K puu value for the prodrug (0.07). Theoretically, after adequate incubation time for the ester to completely convert to the corresponding diacid, the K puu This article has not been copyedited and formatted. The final version may differ from this version. value of the diacid will drop to a similar value as observed when the cells are incubated with the diacid itself.
To quantitatively understand the cellular distribution process of the ester and the diacid, a computational model was developed to evaluate the K puu and the half-life of both molecules in human hepatocytes (Figure 4) . The K puu of the diacid was estimated to be 3, and its half-life in the hepatocytes to be 40 minutes. The passive permeability of the prodrug was 60 times higher than that of diacid (0.012 vs. 2x10 -4 mm/min), consistent with negatively charged characteristics of the diacid and increased lipophilicity of the ester. The hydrolysis rate constant of the prodrug was predicted to be as high as 57 min -1 , resulting in a very short half-life of a few seconds. This disappearance rate of the prodrug was much higher than the appearance rate, leading to a low K puu (0.07).
Time to Steady State for K puu Measurement
The ratio between unbound drug concentration in cells and unbound drug concentration in medium (C u,cell /C u,mdium ) of PF-06649298 was determined using SLC13A5 HEK293 cells at different time points to assess how much time is required to reach steady state in this system (Figure 7) . C u,cell /C u,mdium increases with incubation time as molecules continue to be actively transported into the cells by SLC13A5. 
Impact of Substrate Concentration on K puu
Impact of substrate concentration on K puu was evaluated using PF-06649298 in human hepatocytes. Above a certain concentration (~5 µM in this case), lower K puu values were observed in human hepatocytes with increasing test compound concentrations (Figure 8 ).
This is potentially due to saturation of the SLC13A5 transporter at high concentrations leading to decrease in K puu . 
Discussion
Drug disposition and trafficking in cells is intricate and complex (Figure 1 ). Uptake transporters can increase the intracellular free drug concentration, while efflux transporters can reduce it. Cell membrane potential, pH gradient, binding to proteins and lipids, metabolism, lysosomal trapping and disposition in other subcellular compartments can affect the intracellular free drug concentration and K puu . Intracellular free drug concentration measured by most methods represents an average free drug concentration of all the subcellular compartments. For carboxylic acids, since they have minimal lysosomal trapping and mitochondria accumulation, intracellular free drug concentration is a good surrogate for cytosolic drug concentration in hepatocytes. A number of in vitro methods have been developed to measure in vitro K puu (Figure 2) , however, validation of the methods with in vitro or in vivo pharmacology or PK data has not been thoroughly investigated. One of the validation studies used HMG-CoA reductase inhibition IC 50 ratio from both rat hepatocytes and liver microsomes as a surrogate for K puu of statins (OATP substrates) and compared it to both the kinetic (Yabe et al., 2011) and the temperature K puu methods (Shitara et al., 2013) . The results showed that the kinetic method tended to overestimate the K puu , because metabolism and efflux were not considered in the method. Clearly, cross validation of the K puu methods is important using various in vitro and in vivo pharmacological and PK approaches. In this study, a number of diacids were evaluated in the SLC13A transporter systems. These are ideal compounds for the study, as they are metabolically stable and have low passive permeability. Uptake is the main process governing the K puu of the compounds. In some of the studies, steady state was assumed to have been achieved based on time course data. Both the in vitro SLC13A5 inhibition data and in vivo liver-to-plasma ratio data suggest that the in vitro binding K puu method provides reliable measure of the intracellular free drug concentration and good IVIVE has been established with rat suspension hepatocytes containing 4% fatty acid free BSA. This is the first time that a direct validation of the method is reported with in vitro and in vivo pharmacological and exposure/PK data.
A direct translation of the in vitro K puu to the in vivo K puu (measured from IV infusion study) is possible when a number of assumptions are met. The in vitro K puu can be expressed using the sequential clearance equation (Shitara et al., 2006; Watanabe et al., 2010; Yabe et al., 2011) . The in vivo K puu between the hepatocytes and the hepatic capillary is expressed by the same equation. However, in an IV infusion, artery blood is sampled rather than hepatic capillaries. Since liver blood flow is only about 20% of cardiac output, the concentration difference at the two different locations will lead to different estimation of the in vivo K puu . However, in special cases, in vivo and in vitro K puu is similar. For example, if the compound has minimal metabolism by the liver and no biliary clearance, the in vivo K puu will be a result of drug partition between hepatocytes and hepatic capillaries, and the blood flow in (arterial blood) and out of the liver (hepatic capillary blood) will have the same drug concentrations at the steady state.
Therefore, the in vivo K puu measured in an IV infusion study can be expressed using the same equation as that from the in vitro assay. Under these conditions, when the passive permeability and active uptake rates are comparable in the in vitro and in vivo settings, the K puu values will be similar as well. This appears to be the case for the SLC13A transport of the diacids. A number of studies have shown that certain transporters are down regulated or internalized in cryopreserved hepatocytes (Bow et al., 2008) . In vitro hepatocyte systems tend to underestimate in vivo K puu for OATP substrates (Morse Bridget et al., 2015) , and typically, scaling factors are needed to more accurately predict in vivo outcomes (Li et al., 2014) . However, in this case, the in vitro cryopreserved suspension rat hepatocyte system appears to be able to predict in vivo rat K puu reasonably well. This might be due to the unique properties of the SLC13A transporters, which may behave differently than
OATPs. Further investigation of IVIVE mediated by OATP transporter uptake using hepatocyte suspension systems will provide additional insight. 
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